Prosper Maposa, MBA

Associate Research Scientist in Business Development

With a wealth of experience, Prosper served as the Business Development Lead for the largest vertically integrated pharmaceutical company in Zimbabwe. During his tenure, he demonstrated exceptional leadership skills by successfully leading regional expansion initiatives and playing a pivotal role in the development of new markets and products. Prosper’s professional journey also includes valuable experience as a Research Pharmacist, specializing in nanomedicine and public health research. His contributions to various national and international organizations, such as the International Pharmaceutical Federation and the World Economic Forum’s Global Shapers community, have further highlighted his ability to lead teams and spearhead impactful projects. Prosper is also an active member of the National Pharmaceutical Society. At Evidinno, Prosper assumes key responsibilities including strategic consulting, contracting, and the conceptualization of project proposals. He leverages his expertise to assist Evidinno’s clients in achieving their business objectives. His unique combination of pharmaceutical knowledge, health economics expertise, and business acumen contributes to the success of Evidinno and the clients it serves. Prosper holds a Master of Science (Msc) in Health Economics from the University of Aberdeen in the UK, and a Master of Business Administration (MBA) from Quantic School of Business and Technology in Washington.

Interests/Hobbies: Chess, travelling, and volunteering

Michael del Aguila

Michael del Aguila comes to Evidinno with 25 years experience in consulting and work inside Life Sciences companies in support of market access and real world evidence generation.  This includes executive positions at Roche, Genentech, Bristol-Myers Squibb and Gilead. 

In BioPharma Michael led teams responsible for sponsored real world evidence and HEOR clinical and observational studies, as well as market access and pricing. His executive leadership in consulting services has included those same domains.

He is pleased to have the opportunity to lead Evidinno’s expansion in product offerings and customer base as we continue our growth trajectory. 

Interests/hobbies: Theater, live music, hiking and running

Jean Paul Collet

Jean-Paul is the Chief Scientific Officer at Evidinno. JP is a trained pediatrician with MSc in Health Economics and PhD in Epidemiology from McGill University. He’s been a Professor and Associate Head Research in the Department of Pediatrics at UBC since 2006. JP’s career in clinical research has been associated with receiving many competing grants (over $30 million), the supervision of over 50 students completing MSc, PhD or Postdoc, and numerous publications (200+) with many of them related to drug evaluation methodology, economic impact and outcomes research.

Interests/hobbies: Practicing Tai Chi and Hiking; Holistic approach for self-development; Philosophy

Masoud Pourrahmat

Masoud Pourrahmat acts as the Head of Operations at Evidinno. With a career spanning over a decade, he possesses extensive expertise in the field of HEOR. Masoud has demonstrated exceptional competence in overseeing and executing targeted or systematic literature reviews, meta-analyses, network meta-analyses, and surrogacy analyses of clinical outcomes. His contributions have encompassed diverse areas such as oncology, neurology, cardiology, endocrinology, immunology, and digital health, among others.

Interests/hobbies: Reading, history, cooking.

Mir Sohail Fazeli

Dr. Mir Sohail Fazeli is the President and Managing Director at Evidinno Outcomes Research Inc. He has over two decades of experience working within academia and industry acting as the principal investigator, project lead, and medical research consultant. His work in evidence synthesis covers a diverse range of methodologies, including systematic and targeted literature reviews of clinical trials and observational studies, meta-analyses, network meta-analyses, and complex statistical modelling studies.